XML 46 R40.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Development and License Agreements - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended
--- | --- | ---
Oct. 31, 2023 | May 31, 2021 | Mar. 31, 2021 | Sep. 30, 2019 | Mar. 31, 2024 | Mar. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Research and development expense |  |  |  |  | $ 23,704,000 | $ 20,180,000
License and Stock Purchase Agreement | AbbVie |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Future milestone payment |  |  |  |  | 0 |
Non refundable upfront fee |  |  |  | $ 600,000 |  |
License and Stock Purchase Agreement | AbbVie | Maximum |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Future payments upon the achievement of certain development |  |  |  | 18,000,000 |  |
Future payments upon commercialization |  |  |  | 45,000,000 |  |
Future payments upon sales based milestones |  |  |  | $ 87,500,000 |  |
License Agreement | Roche |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Future milestone payment |  |  |  |  | 0 |
Non-refundable upfront payment |  | $ 4,000,000 | $ 500,000 |  |  |
Additional consideration upon achievement of certain development and commercial milestones |  |  | 120,000,000 |  |  |
License Agreement | Mabwell |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Future milestone payment | $ 5,000,000 |  |  |  |  |
Research and development expense |  |  |  |  | 0 | 10,000,000
Upfront payment |  |  |  |  |  | $ 10,000,000
License Agreement | Mabwell | Maximum |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Certain development and regulatory milestone payments |  |  |  |  | 127,500,000 |
Certain commercial milestone payments for certain licensed antibody product net sales achievements |  |  |  |  | $ 275,000,000 |
Development and Regulatory Milestone First Indication | License Agreement | Roche |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Contingent payments |  |  | 50,000,000 |  |  |
Development and Regulatory Milestone Second Indication | License Agreement | Roche |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Contingent payments |  |  | $ 35,000,000 |  |  |

X
- Definition Additional consideration upon achievement of certain development and commercial milestones. + References No definition available. + Details
Name: | iron_AdditionalConsiderationUponAchievementOfCertainDevelopmentAndCommercialMilestones
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Certain commercial milestone payments for certain licensed antibody product net sales achievements. + References No definition available. + Details
Name: | iron_CertainCommercialMilestonePaymentsForCertainLicensedAntibodyProductNetSalesAchievements
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Certain development and regulatory milestone payments. + References No definition available. + Details
Name: | iron_Certaindevelopmentandregulatorymilestonepayments
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contingent Payments. + References No definition available. + Details
Name: | iron_ContingentPayments
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future milestone payment. + References No definition available. + Details
Name: | iron_FutureMilestonePayment
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future payments upon commercialization. + References No definition available. + Details
Name: | iron_FuturePaymentsUponCommercialization
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future payments upon sales-based milestones. + References No definition available. + Details
Name: | iron_FuturePaymentsUponSalesBasedMilestones
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future payments upon the achievement of certain development. + References No definition available. + Details
Name: | iron_FuturePaymentsUponTheAchievementOfCertainDevelopment
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable upfront fee. + References No definition available. + Details
Name: | iron_NonRefundableUpfrontFee
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront non-refundable payment. + References No definition available. + Details
Name: | iron_UpfrontNonRefundablePayment
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | iron_UpfrontPayment
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=iron_LicenseAndStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_AbbvieDeutschlandGmbhCoKgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=iron_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_MabwellTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneFirstIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneSecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |